Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 199

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Non-small cell lung cancer

Not recruiting

Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Bergenbio ASA

Hormone-refractory prostate cancer+2

Not recruiting

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Carcinoid syndrome

Not recruiting

Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Acetate
  • Sponsor:Crinetics Pharmaceuticals Inc.

Osteosarcoma metastatic+3

Not recruiting

Study on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Regorafenib
  • Sponsor:Instytut Matki I Dziecka

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Mantle cell lymphoma recurrent+1

Not recruiting

Study on Loncastuximab Tesirine for Patients with Relapsed or Refractory Mantle Cell Lymphoma After Immunochemotherapy with Rituximab, Bendamustine, and Cytarabine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Loncastuximab Tesirine
  • Sponsor:Fondazione Italiana Linfomi Ets

Bladder cancer

Not recruiting

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Grupo Espanol De Oncologia Genitourinaria-Socug

Neoplasm malignant

Not recruiting

Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:Pfizer Inc.

Prostate cancer

Not recruiting

Study Comparing Degarelix and Drug Combination with Radiotherapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Malignant melanoma

Not recruiting

Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of Tecaginlimab and Pembrolizumab with Radiotherapy for Patients with Metastatic Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Prostate cancer

Not recruiting

Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Institut Bergonie

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.